RetinAI Medical
RetinAI is transforming ophthalmology through innovative AI-powered solutions that enhance disease understanding and patient care.
Company facts
- Founded
- 2017
- Headquarters
- Switzerland
- CEO
- Carlos Ciller
About
RetinAI Medical AG, founded in early 2017, is a Swiss company committed to enhancing patient outcomes in ophthalmology through innovative software solutions. The company focuses on developing technologies that collect, analyze, and organize health data. Their flagship product, RetinAI Discovery®, is designed to facilitate seamless integration of artificial intelligence into clinical workflows, thus elevating the standard of patient care. By harnessing the power of data and advanced algorithms, RetinAI aims to improve the precision of diagnoses and outcomes for patients suffering from vision-threatening diseases. RetinAI caters to a broad spectrum of needs in healthcare, from research and development support in pharmaceuticals to clinical studies, thus paving the way for advancements in understanding and treating a variety of eye conditions. With its commitment to excellence, RetinAI has achieved several milestones, including regulatory compliance with the EU Medical Device Regulation. The company is a pioneer in AI applications in medicine, ensuring that every clinical data point is turned into actionable insights for healthcare practitioners. This, in turn, fosters better patient management and promotes proactive care strategies.